Get started
EUROPEAN MEDICAL SOLUTIONEUROPEAN MEDICAL SOLUTIONEUROPEAN MEDICAL SOLUTION

EUROPEAN MEDICAL SOLUTION

No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

ALEMS fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

European Medical Solutions is a clinical stage biopharmaceutical company, which engages in the research and development of immunotherapy treatments for environmental and food allergies. Its products include gp-ASIT+, which is developed for the treatment of allergic rhinitis due to grass pollen; hdm-ASIT+, for the treatment of house dust mite allergy; and pnt-ASIT+for the treatment of peanut allergy. The company was founded by Thierry Legon in 1997 and is headquartered in Liege, Belgium.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
ALEMS has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company